Table 3.
Serotype | Virus | Mouse | Mouse | Route | Outcome | Dose | Reference |
---|---|---|---|---|---|---|---|
DENV-2 | D2Y98P | AG129 | AG129 | i.p. | Mortality | ≥106 PFU | [59] |
D2Y98P-PP1 | AG129 | AG129 | s.c. | Mortality | ≥105 PFU | [61] | |
AG129 | AG129 | s.c. | Mortality | ADE + 103 PFU | [65] | ||
D2S10 | AG129 | AG129 | i.v. | Mortality | ≥107 PFU | [40][55] | |
AG129 | AG129 | i.v. | Mortality | ADE + 105–106PFU | [55] | ||
IFNAR−/− | IFNAR−/− | i.v. | Mortality (60%) | 107 PFU | [43] | ||
IFNAR−/− | IFNAR−/− | i.v. | Mortality | ADE + 106–107 PFU | [43] | ||
AGB6 | AGB6 | i.p | Mortality | 106.4 PFU | [75] | ||
A129 | A129 | i.p | Mortality | 107.4 PFU | [75] | ||
Mavs−/− | Mavs−/− | i.p | Survival | 107.5 PFU | [75] | ||
E124/128-IC | AG129 | AG129 | i.v. | Mortality | 1011.2 GE | [42] | |
D220 | IFNAR−/− | IFNAR−/− | i.v. | Mortality (60%) | 107 PFU | [43] | |
IFNAR−/− | IFNAR−/− | i.v. | Mortality | ADE + 105–106PFU | [43] | ||
A129 | A129 | i.v. | Mortality | 107 PFU | [43] | ||
A129 | A129 | i.v. | Mortality | ADE + 105–106PFU | [43] | ||
S221 | AG129 | AG129 | i.v. | Mortality | ≥109 GE | [54], [49],[47] | |
AG129 | AG129 | i.v. | Mortality | ADE + 108.7 GE | [54] | ||
IFNAR−/− | IFNAR−/− | i.v. | Mortality | 1012GE | [44] | ||
A129 | A129 | i.v. | Mortality | 1012 GE | [47] | ||
STAT1−/− | STAT1−/− | i.v. | Mortality | 1012 GE | [49] | ||
STAT2−/− | STAT2s−/− | i.v. | Survival | ≤1012 GE | [49] | ||
STAT1−/−2−/− | STAT1−/−2−/− | i.v. | Mortality | 1010 GE | [49] | ||
STAT1−/−/AR | STAT1−/−/AR | i.v. | Mortality | 1010 GE | [49] | ||
STAT1−/−/GR | STAT1−/−/GR | i.v. | Survival | ≤1010 GE | [49] | ||
IRF3−/− | IRF3−/− | i.v. | Survival | ≤1012GE | [48] | ||
IRF7−/− | IRF7−/− | i.v. | Survival | ≤1012GE | [48] | ||
IRF3−/−7−/− | IRF3−/−7−/− | i.v. | Survival | ≤1012GE | [48] | ||
Mavs−/− | Mavs−/− | i.v. | Survival | ≤1012 GE | [44] | ||
D2S20 | AG129 | AG129 | i.v. | Mortality | ≥109GE | [45] | |
IFNAR−/− | IFNAR−/− | i.v. | Mortality | 1011 GE | [45] | ||
DENV-3 | C0360/94 | AG129 | AG129 | i.p. | Mortality | 107.5 PFU | [67] |
DENV-4 | 703–4 | AG129 | AG129 | i.p. | Mortality | 107.3 PFU | [74] |
AG129 | AG129 | i.p. | Mortality | ADE + 106.3 PFU | [74] | ||
TVP-376 | AG129 | AG129 | i.p. | Mortality | ≥107 PFU | [75] | |
AGB6 | AGB6 | i.p. | Mortality (50%/100%) | 106.4 / 107.4 PFU | [75] | ||
A129 | A129 | i.p. | Survival | 107PFU | [75] | ||
Mavs−/− | Mavs−/− | i.p. | Survival | 107.5 PFU | [75] |
Survival: 0–10% death; Mortality: 75–100% death unless otherwise stated.
Inoculum of virus required to achieve the outcome. (Approximately 5×104 GE / PFU [44]).
Abbreviations: intraperitoneal (i.p.), subcutaneous (s.c.), intravenous (i.v.)